New combo pill aims to boost diabetes remission in Early-Stage patients

NCT ID NCT06888050

Recruiting now Disease control Sponsor: Zhejiang Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 35 times

Summary

This study compares a new once-daily combination pill (henagliflozin plus metformin) against standard metformin pills in 268 adults newly diagnosed with type 2 diabetes. The goal is to see if the combo better controls blood sugar, reduces weight, and increases the chance of diabetes remission over 24 weeks. Participants must be 18-75, with HbA1c between 7-9%, and diagnosed within the last 2 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEW-ONSET TYPE 2 DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Zhejiang Provincial People's Hospital
RECRUITING

Hangzhou, Zhejiang, 310000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEW-ONSET TYPE 2 DIABETES NEW-ONSET TYPE 2 DIABETES